Ruxolitinib in steroid refractory graft-vs.-host disease: A case report

Journal of Hematology and Oncology

Volumn 9, Issue 1, 2016, Pages

  Maffini, Enrico ^a,b   Giaccone, Luisa ^a,b   Festuccia, Moreno ^a,b   Brunello, Lucia ^a,b   Buondonno, Ilaria ^c   Ferrero, Dario ^a,b   Boccadoro, Mario ^b   Dellacasa, Chiara ^a   Busca, Alessandro ^a   Novero, Domenico ^b   Bruno, Benedetto ^a,b  

^a CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Allogeneic hematopoietic stem cell transplant (HSCT); Case report; Proinflammatory cytokines; Regulatory T cells (Treg); Ruxolitinib; Steroid refractory graft vs. host disease (SR GvHD)

Indexed keywords

BUDESONIDE; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; IDARUBICIN; INTERLEUKIN 6; METHOTREXATE; MYCOPHENOLATE MOFETIL; RUXOLITINIB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; PYRAZOLE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; GASTROINTESTINAL BIOPSY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; REFRACTORY ANEMIA; REMISSION; THROMBOCYTE COUNT; COMPLICATION; DRUG RESISTANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PROCEDURES; REFRACTORY ANEMIA WITH EXCESS BLASTS; SALVAGE THERAPY;

ADRENAL CORTEX HORMONES; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 84982975833     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0298-6     Document Type: Article

References (28)

1. Deeg J. How I, treat refractory acute GVHD. Blood. 2007;109(10):4119-26.
2. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-63.
3. Xhaard A, Rocha V, Bueno B, et al. Steroid refractory acute GVHD: lack of long-term improved survival using new generation anti cytokine treatment. Biol Blood Marrow Transplant. 2012;18(3):406-13.
4. Robin M, Porcher R, de Castro R, et al. Initial liver involvement in acute GVHD is predictive for non relapse mortality. Transplantation. 2009;88:1131-6.
5. Inagaki J, Kodama Y, Fukano R, Noguchi M, Okamura J. Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2015;19(6):652-8.
6. Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplant. 2016;51(2):273-6.
7. Van Groningen LF, Liefferink AM, de Haan AF, Schaap NP, Donnelly JP, Blijlevens NM, van der Velden WJ. Combination therapy with inolimomab and etanercept for severe steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(1):179-82.
8. Park JH, Lee HJ, Kim SR, Song GW, Lee SK, Park SY, Kim KC, Hwang SH, Park JS. Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Korean J Intern Med. 2014;29(5):630-6.
9. Meunier M, Bulabois CE, Thiebaut-Bertrand A, Itzykson R, Carre M, Carras S, Garban F, Cahn JY. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(9):1451-4.
10. Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, Kumar A, Kharfan-Dabaja MA. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant. 2014;20(11):1677-86.
11. Alam N, Atenafu EG, Tse G, Viswabandya A, Gupta V, Kim D, Lipton JH, Messner HA, Kuruvilla J. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus host disease. Clin Transplant. 2013;27(6):930-7.
12. Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010;45:1347-51.
13. Ghez D, Rubio MT, Maillard N, Suarez F, Chandesris MO, Delarue R, et al. Rapamycin for refractory acute graft-versus-host disease. Transplantation. 2009;88:1081-7.
14. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10(2):81-90.
15. Baer PC, Wegner B, Geiger H. Effects of mycophenolic acid on IL-6 expression of human renal proximal and distal tubular cells in vitro. Nephro Dyal Transpl. 2004;19:47-52.
16. Teshima T, Reddy P, Zeiser R. Acute graft-versus-host disease. Biol Blood Marrow Transpl. 2016;22:11-6.
17. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:779-87.
18. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Di Persio JF, Catalano J, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey Jr JH, Arasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Vitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
19. Hasselbach C. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;2:214-20.
20. Teshima T. JAK inhibitors: a home run for GVHD patients? Blood. 2014;123(24):3691-3.
21. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle. 2008;7(4):458-62.
22. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea 3rd EP, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055-66.
23. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS. Differential impact of mammalian target of rapamycin inhibition on CD4 + CD25 + FoxP3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111(1):453-62.
24. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832-42.
25. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroidrefractory graft-versus-host disease after allogeneic stem cell transplantation: a multi-center survey. Leukemia. 2015;29(10):2062-8.
26. Khoury HJ, Kota V, Arellano M et al. Ruxolitinib as sparing agent for steroid-dependent chronic graft-versus-host disease (cGVHD). Presented at: 2016 ASH Annual Meeting; December 5-8, 2015. Orlando, Florida; Abstract 1938.
27. Vertovsek S, Gotlib J, Gupta V, Atallah E, Mascarehas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013;7:13-21.
28. Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R, Nash RA. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(3):154-62.